Making the most of little: India explores new models

India faces many of the same challenges as Brazil and provides an example of an innovative approach to healthcare. The country is leveraging its role as a contract researcher and manufacturer of generic drugs to increase the value of its output, for example by developing branded generic drugs and new formulations for existing drugs. Through “reverse pharmacology” it is developing and launching medications based on its traditional treatments at a fraction of the cost of drugs developed by Western companies—US$50m, compared with US$1bn respectively. Indian companies such as Glenmark are already operating in Brazil and looking to expand this business model there.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week